Minnesota is currently home to 2094 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Brain Vascular and Neural Function Linked to Balance Across the Adult Lifespan
NCT06127667
Recruiting
This is a single-arm, two-visit, non-randomized, cross sectional study identified as an intervention due to the use of a single bout of aerobic exercise to assess cerebrovascular function under the NIH rules. This study is not masked and its primary purpose is to develop a basic science understanding of the relationship between cerebrovascular health and balance control with aging. This study will involve 102 individuals classified as younger adults, middle-aged adults, and older adults who are... Read More
Gender:
ALL
Ages:
Between 21 years and 95 years
Trial Updated:
10/29/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Neurotypical, Cognitively Normal
Register for Updates
Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa
NCT06058520
Recruiting
HS is relatively common in the United States with a prevalence of 0.1-1.0%. 1 HS has a dramatic impact on quality of life, significantly more so than other chronic skin diseases, such as psoriasis or atopic dermatitis (AD). HS also has a large economic impact, due to frequent emergency department and inpatient care utilization, and re-hospitalization rates similar to congestive heart failure. Unfortunately, few treatment options are effective. There is only one currently FDA-approved treatment,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Hidradenitis Suppurativa
Register for Updates
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768
Recruiting
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be bette... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: Sanford Joe Lueken Cancer Center, Bemidji, Minnesota
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Register for Updates
Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia
NCT05727761
Recruiting
This is a Phase IIa oral cavity leukoplakia study of pioglitazone 15mg and metformin 500mg BID for 12 weeks. The primary objective is to determine the clinical and histologic changes of leukoplakia from baseline following a 12 week course of twice daily pioglitazone-metformin. Outcomes are defined as are a reduction of the leukoplakia grade in \> 50% of treated participants and a partial or complete clinical response defined as 50% or greater reduction in the sum of measured targeted lesions. In... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Oral Leukoplakia
Register for Updates
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
NCT06014255
Recruiting
This study evaluates the efficacy, anti-tumor effect, and immunogenicity of neoadjuvant enoblituzumab given before radical prostatectomy. Patients will be randomized to enoblituzumab for a total of 12 weeks beginning 84 days before radical prostatectomy or standard of care arms.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/28/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Prostate Cancer
Register for Updates
Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology
NCT05184569
Recruiting
The purpose of the study is to test the safety and tolerability of twice daily Verdiperstat in patients with semantic variant primary progressive aphasia (svPPA) due to frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP). Three-fourths of the participants will receive Verdiperstat and one-fourth will receive Placebo during the 24-week treatment duration.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/28/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Semantic Dementia
Register for Updates
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
NCT05108298
Recruiting
The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
10/28/2024
Locations: Fairview Ridges Hospital, Burnsville, Minnesota
Conditions: Breast Cancer, NOS, CNS Primary Tumor, NOS, Cervical Cancer, NOS, Colorectal Cancer, NOS, Leukemia, NOS, Lymphoma, NOS, Miscellaneous Neoplasm, NOS, Non-Rhabdomyosarcoma Soft Tissue Sarcoma, NOS, Testicular Nonseminomatous Germ Cell Tumor, NOS, Thyroid Cancer, NOS, Melanoma, Bone Cancer, NOS
Register for Updates
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
NCT05907954
Recruiting
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Uveal Melanoma
Register for Updates
A Study of Cardiovascular Disparities in the Greater Mankato Somali Community to Prevent Hypertension
NCT05873153
Recruiting
The purpose of this research is to develop ways to reduce hypertension-management-related disparities in the Greater Mankato Area Somali population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: Erin Westfall, Mankato, Minnesota
Conditions: Hypertension
Register for Updates
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
NCT05476497
Recruiting
This phase I clinical trial is designed to evaluate the safety and tolerability of VLP Peanut in healthy subjects and in subjects with peanut allergy (PA). This clinical trial will evaluate the immunotoxicity profile of VLP Peanut in healthy subjects and assess the immunotoxicity profile and the degree of reactogenicity (allergenicity) in subjects with PA. This clinical trial will also explore preliminary proof of efficacy of VLP Peanut in subjects with PA.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/24/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Peanut Allergy
Register for Updates
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
NCT04851119
Recruiting
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells by blocking the signals passed from one molecule to another inside a cell that tell a cell to grow.
Gender:
ALL
Ages:
Between 12 months and 30 years
Trial Updated:
10/23/2024
Locations: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Colorectal Carcinoma, Endometrial Carcinoma, Melanoma, Neuroblastoma, Ovarian Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Desmoid Fibromatosis, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Refractory Desmoid Fibromatosis, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Solid Pseudopapillary Neoplasm of the Pancreas, Wilms Tumor
Register for Updates
Treatment of ARDS With Instilled T3
NCT04115514
Recruiting
It is hypothesized that instillation of Liothyronine Sodium (T3) into the airspace will be safe, well tolerated, and will increase alveolar fluid clearance and decrease inflammation in patients with ARDS, reflected in improved oxygenation index (OI) and oxygenation saturation index (OSI).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2024
Locations: M Health Fairview Southdale Hospital, Edina, Minnesota
Conditions: ARDS, Human, Lung, Wet, Thyroid, Pulmonary Edema, Lung Inflammation
Register for Updates